Evidence suggests commercial health plans are more likely to delay specialty drug coverage decisions in response to FDA ...
The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results